| Publications | PubMed=2300817; DOI=10.1126/science.2300817
Jeffrey M. Trent, Eric John Stanbridge, Heyoung L. McBride, Eckart U. Meese, Graham Casey, Diana E. Araujo, Colette M. Witkowski, Raymond B. Nagle;
Tumorigenicity in human melanoma cell lines controlled by introduction of human chromosome 6.
Science 247:568-571(1990) PubMed=2068080; DOI=10.1073/pnas.88.14.6028; PMCID=PMC52015
Isabelle Cornil, Dan Theodorescu, Shan Man, Meenhard Herlyn, Jadranka Adriana Jambrosic, Robert S. Kerbel;
Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression.
Proc. Natl. Acad. Sci. U.S.A. 88:6028-6032(1991) PubMed=9598804; DOI=10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N
Graeme J. Walker, Jose F. Flores, J. Michael Glendening, Amy Hsiu-Ti Lin, Isabel D.C. Markl, Jane W. Fountain;
Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets.
Genes Chromosomes Cancer 22:157-163(1998) PubMed=9692547; DOI=10.1038/sj.onc.1201881
Hensin Tsao, Xue Zhang, Eric Benoit, Frank G. Haluska;
Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines.
Oncogene 16:3397-3402(1998) PubMed=9823299
Javed Khan, Richard M. Simon, Michael Bittner, Yi-Dong Chen, Stephen B. Leighton, Thomas Pohida, Paul D. Smith, Yuan Jiang, Gerald C. Gooden, Jeffrey M. Trent, Paul S. Meltzer;
Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays.
Cancer Res. 58:5009-5013(1998) PubMed=9973934; DOI=10.1016/S0165-4608(98)00122-8
Mark A. Nelson, Maria E. Ariza, Jin-Ming Yang, Floyd H. Thompson, Raymond Taetle, Jeffrey M. Trent, Julie Wymer, Kathy S. Massey-Brown, Marianne Broome-Powell, John Easton, Jill M. Lahti, Vincent J. Kidd;
Abnormalities in the p34cdc2-related PITSLRE protein kinase gene complex (CDC2L) on chromosome band 1p36 in melanoma.
Cancer Genet. Cytogenet. 108:91-99(1999) PubMed=10766161
Hensin Tsao, Xue Zhang, Kianna Fowlkes, Frank G. Haluska;
Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines.
Cancer Res. 60:1800-1804(2000) PubMed=10952317; DOI=10.1038/35020115
Michael Bittner, Paul S. Meltzer, Yi-Dong Chen, Yuan Jiang, Elisabeth A. Seftor, Mary J.C. Hendrix, Michael D. Radmacher, Richard M. Simon, Zohar Yakhini, Amir Ben-Dor, Nick Sampas ...Show all 28 authors... , Edward Russell Dougherty, Ena Wang, Francesco M. Marincola, Gerald C. Gooden, John Lueders, Arthur Glatfelter, Pamela M. Pollock, John D. Carpten, Elizabeth M. Gillanders, Darryl Leja, Kathleen Dietrich, Christian Beaudry, Michael E. Berens, David Samuel Alberts, Vernon K. Sondak, Nicholas K. Hayward, Jeffrey M. Trent; Show fewer authors
Molecular classification of cutaneous malignant melanoma by gene expression profiling.
Nature 406:536-540(2000) PubMed=12115485; DOI=10.1002/ijc.10422
Yong-Mei Feng, Jia-Qi Shi, Alisa Miriam Goldstein, Margaret Anne Tucker, Mark A. Nelson;
Analysis of mutations and identification of several polymorphisms in the putative promoter region of the P34CDC2-related CDC2L1 gene located at 1P36 in melanoma cell lines and melanoma families.
Int. J. Cancer 99:834-838(2002) PubMed=15009714; DOI=10.1046/j.0022-202X.2004.22243.x; PMCID=PMC2586668
Hensin Tsao, Vikas Goel, Heng Wu, Guang Yang, Frank G. Haluska;
Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma.
J. Invest. Dermatol. 122:337-341(2004) PubMed=19383853; DOI=10.1158/1535-7163.MCT-08-1030; PMCID=PMC3128982
David M. Su, Qiu-Yang Zhang, Xue-Xi Wang, Ping He, Yue-Lin Jack Zhu, Jian-Xiong Zhao, Owen M. Rennert, Yan A. Su;
Two types of human malignant melanoma cell lines revealed by expression patterns of mitochondrial and survival-apoptosis genes: implications for malignant melanoma therapy.
Mol. Cancer Ther. 8:1292-1304(2009) PubMed=23039341; DOI=10.1186/1476-4598-11-75; PMCID=PMC3554420
Sara A. Byron, David C. Loch, Candice L. Wellens, Andreas Wortmann, Jia-Yi Wu, John Wang, Kenichi Nomoto, Pamela M. Pollock;
Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.
Mol. Cancer 11:75.1-75.15(2012) PubMed=24879157; DOI=10.4161/auto.28594; PMCID=PMC4091172
Megan L. Goodall, Tong Wang, Katie R. Martin, Matthew G. Kortus, Audra L. Kauffman, Jeffrey M. Trent, Stephen Gately, Jeffrey P. MacKeigan;
Development of potent autophagy inhibitors that sensitize oncogenic BRAF V600E mutant melanoma tumor cells to vemurafenib.
Autophagy 10:1120-1136(2014) |
|---|
